Cargando…

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms

Background. Platinum-based chemotherapy is the mainstay of front-line treatment of patients affected by pluri-metastatic intermediate/high grade NeuroEndocrine Neoplasms (NENs). However, there are no standard second-line treatments at disease progression. Previous clinical experiences have evidenced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tafuto, Salvatore, von Arx, Claudia, Capozzi, Monica, Tatangelo, Fabiana, Mura, Manuela, Modica, Roberta, Barretta, Maria Luisa, Di Sarno, Antonella, Tornesello, Maria Lina, Colao, Annamaria, Ottaiano, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723560/ https://www.ncbi.nlm.nih.gov/pubmed/31443197 http://dx.doi.org/10.3390/jcm8081224

Ejemplares similares

Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
por: von Arx, Claudia, et al.
Publicado: (2019)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016)

Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
por: von Arx, Claudia, et al.
Publicado: (2020)

Hepatic arterial embolization in patients with neuroendocrine tumors
por: Del Prete, Michela, et al.
Publicado: (2014)

Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
por: Capozzi, Monica, et al.
Publicado: (2019)

Evaluation of MGMT Gene Methylation in Neuroendocrine Neoplasms
por: Della Monica, Rosa, et al.
Publicado: (2022)

Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis
por: Melone, Viola, et al.
Publicado: (2022)

Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management
por: Altieri, Barbara, et al.
Publicado: (2019)

Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches
por: Lania, Andrea, et al.
Publicado: (2021)

Prognostic Assessment of Gastropancreatic Neuroendocrine Neoplasm: Prospects and Limits of Radiomics
por: De Muzio, Federica, et al.
Publicado: (2023)

A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
por: De Divitiis, Chiara, et al.
Publicado: (2015)

Malignant Sinonasal Tumors: Update on Histological and Clinical Management
por: Bracigliano, Alessandra, et al.
Publicado: (2021)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature
por: Giannetta, Elisa, et al.
Publicado: (2022)

Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers
por: Giannetta, Elisa, et al.
Publicado: (2021)

Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
por: Fanciulli, Giuseppe, et al.
Publicado: (2022)

Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target
por: Modica, Roberta, et al.
Publicado: (2022)

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors
por: Altieri, Barbara, et al.
Publicado: (2020)

Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead
por: Colao, Annamaria, et al.
Publicado: (2020)

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life
por: Faggiano, Antongiulio, et al.
Publicado: (2015)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications
por: Vitale, Giovanni, et al.
Publicado: (2021)

Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy
por: Ottaiano, Alessandro, et al.
Publicado: (2017)

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues
por: Gallo, Marco, et al.
Publicado: (2021)

Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
por: Tena, Isabel, et al.
Publicado: (2018)

Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
por: Wong, Eric T., et al.
Publicado: (2016)

Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?
por: Giannetta, Elisa, et al.
Publicado: (2021)

CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR
por: Circelli, Luisa, et al.
Publicado: (2016)

Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask
por: Albertelli, Manuela, et al.
Publicado: (2021)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors
por: Büsker, Sören, et al.
Publicado: (2022)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?
por: Barrea, Luigi, et al.
Publicado: (2021)

Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study
por: Modica, R., et al.
Publicado: (2022)

Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis
por: Lu, Yaoheng, et al.
Publicado: (2018)

Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience
por: Douangprachanh, Sathathone, et al.
Publicado: (2022)

Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists
por: Pellegrino, Fabio, et al.
Publicado: (2023)

From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?
por: Vitale, Giovanni, et al.
Publicado: (2020)

The Effects of Radioligand Therapy on Quality of Life and Sexual Function in Patients with Neuroendocrine Neoplasms
por: Malandrino, Pasqualino, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vjmjn8dokvis7is172qrk6prkd